Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

1,471

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

RSVpreF Vaccine

RSV Vaccine

OTHER

Placebo

Placebo

BIOLOGICAL

Seasonal Inactivated Influenza Vaccine

SIIV

Trial Locations (33)

2010

Holdsworth House Medical Practice, Darlinghurst

2019

Emeritus Research, Botany

2031

Scientia Clinical Research, Randwick

2100

Northern Beaches Clinical Research, Brookvale

2145

Westmead Hospital, Westmead

2148

Paratus Clinical Research Western Sydney, Blacktown

2259

Paratus Clinical Research Central Coast, Kanwal

2291

The AIM Centre / Hunter Diabetes Centre, Merewether

2292

Genesis Research Services, Broadmeadow

2305

John Hunter Hospital, New Lambton Heights

2450

Northside Health, Coffs Harbour

2617

Paratus Clinical Research Canberra, Bruce

3004

Nucleus Network Brisbane, Melbourne

Nucleus Network Melbourne, Melbourne

3079

Doctors of Ivanhoe, Ivanhoe

3124

Emeritus Research, Camberwell

3128

Box Hill Hospital, Box Hill

3220

Barwon Health, Geelong

4006

Nucleus Network Brisbane, Herston

4010

Paratus Clinical Research Brisbane, Albion

4064

Core Research Group, Brisbane

4068

AusTrials - Taringa, Taringa

Core Research Group, Taringa

4121

AusTrials Wellers Hill, Tarragindi

4222

Griffith University, Gold Coast Campus

4506

USC Clinical Trials Moreton Bay, Morayfield

4556

USC Clinical Trials Centre, Sippy Downs

4740

Mackay Hospital and Health Service, Mackay

5000

CMAX Clinical Research Pty Ltd, Adelaide

6009

Institute for Respiratory Health, Nedlands

6163

Latitude Clinical Research, Spearwood

7000

University of Tasmania, Hobart

NSW 2035

Australian Clinical Research Network, Sydney

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05301322 - Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age | Biotech Hunter | Biotech Hunter